Endonovo Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $7.3M | $-15.8M | $85.9K |
| FY2022 | $7.2M | $-32.2M | — |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $7.3M | $-15.8M | $85.9K |
| FY2022 | $7.2M | $-32.2M | — |